Yang, Tiansong, Yang, Yan, Wang, Delong et al. · Journal of translational medicine · 2019 · DOI
This review examined whether immune system signaling molecules called cytokines could help doctors diagnose or treat ME/CFS. While researchers found that cytokines are abnormal in ME/CFS patients' blood and fluid around the brain, the current evidence shows these markers are not reliable enough to use alone for diagnosis. The review suggests that measuring multiple cytokines together might help doctors better understand what's happening in individual patients, but cytokines are not yet proven as effective treatment targets.
This review is important because it objectively evaluates whether cytokine testing could become a clinical tool for ME/CFS diagnosis and treatment. Understanding the current limitations of cytokine research helps patients and clinicians make informed decisions about available testing and sets realistic expectations for future biomarker development.
This review does not prove that cytokines are useless in ME/CFS research—rather, it shows they are not yet ready for independent clinical use. The study does not establish that cytokines play no role in ME/CFS pathology, only that current evidence is insufficient for diagnostic or therapeutic application. Correlation between cytokine abnormalities and disease severity does not establish causation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.